Cancer News and Research

Latest Cancer News and Research

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Amgen today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF).

3 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

Red Hat receives CEO Cancer Gold Standard accreditation for workplace actions to reduce cancer

Red Hat, the world's leading provider of open source software solutions, headquartered in Raleigh, NC, is leading by example when it comes to promoting workplace wellness and encouraging healthier behavior.

3 Jun 2013

First Edition: June 3, 2013

Today's early morning highlights from major news organizations, including a number of stories detail health law implementation developments.

3 Jun 2013

NJIT professor emphasizes how point of care healthcare can reduce illness, improve quality of life

NJIT Distinguished Professor and electrical engineer Atam Dhawan hits the lecture trail again this summer as a distinguished speaker for an IEEE life sciences lecture series.

3 Jun 2013

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

Ohr Pharmaceutical, Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced a 1-for-3 reverse split of the Company's issued and outstanding common stock. The reverse stock split will be effective prior to the stock market opening on Monday, June 3, 2013.

3 Jun 2013

It is possible to reduce salt content without reducing the taste

It is entirely possible to reduce the salt content in a range of foods by up to 30% without reducing the taste.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Majority of U.S. oncologists report satisfaction with careers, but still experience symptom of burnout

Even though a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, a Mayo Clinic-led study has found. The study was released during the American Society of Clinical Oncology's annual meeting in Chicago.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

Researchers solve two longstanding challenges in liver tissue engineering

Prometheus, the mythological figure who stole fire from the gods, was punished for this theft by being bound to a rock. Each day, an eagle swept down and fed on his liver, which then grew back to be eaten again the next day.

3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Cancer News and Research

Latest Cancer News and Research

Amgen reports encouraging results from talimogene laherparepvec phase 3 study in patients with metastatic melanoma

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

Red Hat receives CEO Cancer Gold Standard accreditation for workplace actions to reduce cancer

First Edition: June 3, 2013

NJIT professor emphasizes how point of care healthcare can reduce illness, improve quality of life

Ohr Pharmaceutical declares 1-for-3 reverse split of its outstanding common stock

It is possible to reduce salt content without reducing the taste

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Majority of U.S. oncologists report satisfaction with careers, but still experience symptom of burnout

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Researchers solve two longstanding challenges in liver tissue engineering

Study investigates gene expression signature to predict response to bevacizumab

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Human tumors with MET amplification respond to MET inhibitor drugs

Study finds HER2 irregularities in 14 different advanced solid tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in